Alkermes plc Total Liabilities
Alkermes plc total liabilities. Based on the latest financial reports, Alkermes plc (8AK) has total liabilities worth €2.51 Billion EUR (≈ $2.93 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See defensive interval ratio of Alkermes plc to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Alkermes plc (2013–2025)
Total liabilities of Alkermes plc from 2013 to 2025. This chart illustrates how Alkermes plc's total liabilities have evolved over time, based on quarterly financial data. Check 8AK financial resilience to evaluate the company's liquid asset resilience ratio.
Alkermes plc Competitors by Total Liabilities
The table below lists competitors of Alkermes plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$8.29 Billion |
|
Schaeffler AG
XETRA:SHA0
|
Germany | €18.85 Billion |
|
Lottomatica Group SpA
NYSE:LOTMY
|
USA | $3.13 Billion |
|
Unicaja Banco SA
MC:UNI
|
Spain | €91.34 Billion |
|
Fluor Corporation
NYSE:FLR
|
USA | $4.75 Billion |
|
Huadong Medicine Co Ltd
SHE:000963
|
China | CN¥15.43 Billion |
|
Korea Aerospace Industries
KO:047810
|
Korea | ₩8.23 Trillion |
|
Henan Shijia Photons Technology Co Ltd
SHG:688313
|
China | CN¥1.07 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Alkermes plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Alkermes plc.
Liquidity & Leverage Metrics
Alkermes plc Total Liabilities Ratios Explained
Alkermes plc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alkermes plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alkermes plc (2013–2025)
The table below shows the annual total liabilities of Alkermes plc from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €667.70 Million ≈ $780.61 Million |
+13.06% |
| 2024-12-31 | €590.59 Million ≈ $690.46 Million |
-36.74% |
| 2023-12-31 | €933.54 Million ≈ $1.09 Billion |
+1.45% |
| 2022-12-31 | €920.23 Million ≈ $1.08 Billion |
+0.91% |
| 2021-12-31 | €911.90 Million ≈ $1.07 Billion |
+39.49% |
| 2018-12-31 | €653.72 Million ≈ $764.27 Million |
+9.98% |
| 2017-12-31 | €594.42 Million ≈ $694.94 Million |
+14.99% |
| 2016-12-31 | €516.94 Million ≈ $604.36 Million |
-4.53% |
| 2015-12-31 | €541.47 Million ≈ $633.03 Million |
+3.69% |
| 2014-12-31 | €522.22 Million ≈ $610.53 Million |
+1.92% |
| 2013-12-31 | €512.40 Million ≈ $599.05 Million |
-- |
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and … Read more